Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.30 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.30 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.30 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.30 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.30 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.30 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.30 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.30 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.30 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.30 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345096 | 0.83 | OPRM1 (0.34) | DPP4DPP8DPP7MAP2K1SIGMAR1 | |
| SCHEMBL3347303 | 0.81 | HSD17B10 (0.41) | KMT2A | |
| SCHEMBL3342680 | 0.79 | MAP2K1 (0.33) | DPP4DPP8DPP7MAP2K1 | |
| SCHEMBL3342647 | 0.78 | MAP2K1 (0.32) | MAP2K1 | |
| SCHEMBL3345219 | 0.76 | GPR88 (0.32) | MAP2K1 | |
| SCHEMBL5645863 | 0.69 | HSD17B10 (0.36) | KMT2A | |
| SCHEMBL3344742 | 0.67 | MC4R (0.32) | — | |
| SCHEMBL3343258 | 0.67 | PSEN1 (0.40) | MAP2K1SIGMAR1 | |
| SCHEMBL3342676 | 0.67 | PSEN1 (0.49) | MAP2K1SIGMAR1 | |
| SCHEMBL14260862 | 0.67 | PSEN1 (0.49) | MAP2K1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1554250-B1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | DPP4 1064/4885DPP8 1312/4885DPP7 519/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | DPP4 210/4885DPP8 972/4885DPP7 247/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | DPP4 792/4885DPP8 923/4885DPP7 318/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | DPP4 1577/4885DPP8 1452/4885DPP7 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.